ABSTRACT
INTRODUCTION
The prevention of perinatal transmission of human immunodeficiency virus (HIV) is an important public health objective. Contact tracing has long been an important tool in the prevention of sexual disease transmission. Concern has been expressed that named reporting or mandatory HIV partner notification may have a detrimental effect on patients' willingness to undergo HIV testing or to enter into the health care delivery system. Partner notification with contact tracing has been shown to Drs identify additional cases of HIV. 1 However, if partner notification results in decreased prenatal HIV testing or care seeking, it may limit the overall benefits with regard to perinatal health.
Whether pregnant women would be less likely to pursue prenatal testing when associated with named reporting or mandatory partner notification has been studied in a limited fashion. 2, 3 A previous preliminary study suggested that there was no decrease in women's consent for prenatal HIV testing when named reporting and mandatory partner notification were instituted. 2 These initial studies were limited in sample size and by the potential bias inherent in an ambulatory design. Patients who found named reporting or partner notification highly unacceptable may have been deterred from entering prenatal care. If prenatal care seeking had been adversely affected, an ambulatory study showing high acceptance rates of prenatal HIV testing would not reflect the overall impact of named reporting and mandatory partner notification.
This study compared the acceptance of prenatal HIV testing among patients admitted to a labor-and-delivery service in the period immediately prior to the institution of named reporting and mandatory partner notification in New York State on July 1, 2000, to the period immediately after the institution of named reporting and mandatory partner notification. The percentage of women who arrived for delivery with no prenatal care was also compared for each period to see if the institution of named reporting and mandatory partner notification was correlated with an increased avoidance of prenatal care.
METHODS
After institutional review board approval was obtained, data regarding HIV testing during pregnancy were analyzed for 5,007 sequential patients admitted to a laborand-delivery service from December 15, 1999, through February 14, 2001, at a tertiary care hospital in Central New York State. Admission logs in labor-anddelivery and birth certificate databases were examined to compile a list of all patients admitted, including those who delivered and antepartum patients, both privately and publicly insured. We excluded 11 patients because they were known to be HIV positive prior to pregnancy and thus would not be eligible for HIV testing during pregnancy. We excluded 8 in the preimplementation phase and 3 in the postimplementation phase. This left a pool of 4,996 patients for analysis (Table 1) .
A uniform institutional protocol for HIV counseling, consistent with state regulations, had been previously implemented and was utilized at all sites. All women were counseled that HIV can be transmitted from mother to child, and that there is effective treatment available to decrease the risk of transmission to the fetus. Risk factors for HIV transmission, the difference between confidential and anonymous testing, and the provisions of New York State law regarding the confidentiality of HIV information were discussed with all patients. The information was reiterated in a written consent that patients signed. All patients presenting for prenatal care on or after June 15, 2000, were identically counseled except for an additional discussion of the new provisions of New York State law regarding named reporting and mandatory partner notification that were to be implemented on July 1, 2000. Thus, patients counseled on or after June 15, 2000, were considered to be in the postimplementation phase.
The new New York State regulations on named reporting and mandatory partner notification require health care providers and laboratories to report to the health department the names of all persons with a new diagnosis of HIV infection.
In addition, the names of all known sexual and needle-sharing partners, including spouses, are to be provided. Partner notification may be performed by the patient or with the assistance of the provider or the public health department. There are specific provisions to allow a delay or deferral of partner notification in cases of domestic violence. Patients were counseled specifically that if they were diagnosed as HIV positive, their name and the name of any identified contacts (including their spouse and/or the father of the baby) would be provided to the public health department. The patients were informed that their partners could be notified by the public health department that they "may have been exposed to someone who has been found to be HIV positive, and they should come in for testing." They were also assured that neither their name nor their physician's name would be given to the partner in the course of partner notification. Patients who refused HIV testing were informed of the availability of expedited intrapartal HIV testing for women of unknown HIV status. Infants born to women of unknown HIV status undergo rapid newborn HIV testing in New York State. Pregnant women who refuse prenatal and intrapartal testing and then deliver an infant who tests positive as a result of rapid newborn testing do not undergo named reporting and mandatory partner notification in New York State. Patients were divided into two groups based on the first date of HIV counseling. The data were obtained by retrospective chart review by professional abstractors. The presence of HIV counseling, the rate of consent for HIV testing, and the percentage of patients completing HIV testing were determined. Patients who initially consented to HIV testing and then later withdrew consent at the time of phlebotomy were considered nonconsenters. Patients who refused HIV testing initially and then later in pregnancy consented to testing prior to delivery were considered consenters. Acceptance of HIV testing was confirmed by verification of laboratory data for all consenting patients. Charts of patients without documented HIV testing were reviewed. Refusal of HIV testing, prenatal care without HIV counseling, or the absence of prenatal care was documented for each patient. The percentage of patients who did not accept prenatal HIV testing was determined for the patients in the period prior to named reporting and mandatory partner notification and was compared to the percentage of patients who did not accept testing after named reporting and mandatory partner notification was instituted. The percentage of women who delivered without prenatal care in both periods was also assessed. Key variables such as acceptance of HIV testing or receipt of prenatal care were verified by the first author.
The sample size was calculated based on the assumption of a 96% rate of acceptance of prenatal HIV testing in the preimplementation period. A two-tailed test of significance at the .05 level, for the study to detect a relative risk of 1.5 for prenatal nonacceptance of HIV testing after the implementation of named reporting and mandatory partner notification, required a sample size of 5,184 patients (2,592 patients in each the pre-and postimplementation period) at 90% power.
Statistical analyses were performed with Epi Info (version 6.04c, Centers for Disease Control and Prevention, Atlanta, GA). Categorical data were analyzed with chi-square analyses with Yates correction for small cell sizes if appropriate. Continuous variables were analyzed with the Student t test. Over 400 variables of obstetric demographic data, maternal risk factors, fetal risk factors, and delivery outcomes were considered. In the bivariate analysis, variables that differed in the pre-and postimplementation phase at a significance level of P ≤ 0.1 were considered potential confounders and were assessed for interaction with the outcome variables. Logistic regression modeling was performed with SPSS software to estimate multivariate odds ratios (ORs) and 95% confidence intervals (CIs). To control for potential confounding, the following variables were included in the logistic regression model: education, insurance payer status, race, tobacco use, age, urban residence, late prenatal care, and preterm delivery.
RESULTS
We excluded 11 patients for known HIV positive status prior to pregnancy. Of the remaining 4,996 charts, all patients with prenatal care received HIV counseling. Of 4,030 patients, 118 (2.9%) did not accept prenatal HIV testing in the preinstitution period. In addition, 59 of 966 patients (6.1%) did not accept prenatal HIV testing in the postinstitution period. There was a significant increase in the percentage of patients who did not accept HIV testing in the period after institution of HIV named reporting and mandatory partner notification (Table 2) , relative risk (RR) = 2.09 (1.54 < RR < 2.83). This remained significant after logistic regression controlled for confounding variables, OR = 1.5 (1.07 < OR < 2.10).
Of 4,030 patients, 14 (0.3%) received no prenatal care in the preinstitution population, and 18 of 966 patients (1.9%) received no prenatal care in the postinstitution population. There was a significant increase in the percentage of patients who did not receive prenatal care after the institution of named reporting and mandatory partner notification (Table 3) , RR = 5.36 (2.68 < RR < 10.75). This remained significant after logistic regression controlled for confounding variables, OR = 3.77 (1.84 < OR < 7.72).
Initial power calculations required the analysis of 5,184 charts to provide 95% confidence and 90% power to detect an absolute difference of 50% in the percentage of patients who did not accept HIV testing. Since the difference between groups was larger than initially calculated, an interim analysis showed significant results, and further chart review to gather additional cases in the postimplementation phase was not performed. 
DISCUSSION
This study contrasts with results of an earlier pilot investigation that reported no decrease in consent for prenatal HIV testing with the institution of named reporting and mandatory partner notification. 2 The present study showed a significant increase in the number of women who did not accept prenatal HIV testing when coupled with named reporting and mandatory partner notification. Our earlier study had a smaller database of patients that could increase the likelihood of a type II error, and this may have contributed to the discrepancy. 2 However, the preliminary study also used an ambulatory design that was unable to assess the impact of prenatal care seeking. The current study found a significant increase in the percentage of patients who avoided prenatal care after named reporting and mandatory partner notification was instituted. Lindsay et al. 4 reported that patients with no prenatal care were at higher risk of being HIV positive and had a lower consent rate for HIV testing even in the absence of named reporting and mandatory partner notification. Like other investigators, we found that factors associated with low socioeconomic status decreased the likelihood of HIV testing. This was further exacerbated by named reporting and mandatory partner notification. If those who were at low risk for HIV infection accepted prenatal care and HIV testing, while those who were at highest risk for HIV infection refused prenatal care, this may have contributed to the discrepancy between the two studies. Rivero et al. 3 performed a study, previously published in abstract form, of 1,543 pregnant patients undergoing prenatal care; they found no difference in the rate of acceptance of HIV testing prior to named reporting and after the initiation of named reporting (87% vs. 86%). Like our earlier study, they used an ambulatory design that was unable to assess prenatal care seeking. Furthermore, Rivero et al. relied on patient self-report regarding the acceptance of HIV testing rather than on a more objective documentation of HIV laboratory data as was used in this study.
Other investigations of name-based reporting have been in distinctly different populations. An earlier investigation of untested gay males living in states with name-based reporting noted that men were significantly more likely (37%) to cite a concern about reporting as a deterrent to testing than those living in states without name-based reporting (11%). 5 For men who have sex with men, testing declined when Louisiana and Tennessee began named HIV reporting. 6 However, pregnant women have additional concerns of fetal well-being and therefore may not respond to named reporting or partner notification in the same way as other groups, such as gay men or even gynecologic patients. For those pregnant women whose only risk factor is unprotected intercourse, a perception of much lower risk of discrimination could alter testing behavior as well.
Many studies examining the factors affecting HIV testing have relied on questionnaires asking those who have self-referred for HIV testing if they would be as likely to have HIV testing if named reporting or partner notification were in effect. This study reports actual, rather than theoretical, decision making. Other study designs have examined the number of HIV tests performed at drug rehabilitation programs or at high-risk sexually transmitted disease clinics. Testing of a single subject multiple times or a variation in the number of patients self-referring to the sites over time may skew the results. The denominator of patients considering testing in these studies is unknown. In our study, all pregnant patients admitted to the hospital were counseled regarding HIV testing. Thus, the denominator is truly population based rather than the more proximate marker of a high-risk clinic population.
Major strengths of this study are the inclusion of all patients admitted rather than a representative sampling that may be subject to bias, the large numbers of diverse patients, and the ability to assess even patients refusing prenatal care. Given the simultaneous implementation of named reporting and mandatory partner notification, it was impossible in our study design to assess the effect of each independently. New York State is one the few states that has instituted mandatory newborn HIV testing. Our results may not be able to be generalized to states without mandatory newborn testing.
In our study population, only 18/5,013 (0.36%) women were HIV positive. Newborn data identified an additional two cases of HIV infection not identified prenatally. This represents a population at relatively low risk for HIV infection. Even in this low-risk population, there is a strong suggestion that the institution of named reporting and mandatory partner notification has significantly impacted the willingness of pregnant patients to undergo HIV testing. Barbacci et al. 7 indicated that elective prenatal testing (in the absence of partner notification) markedly increased the rate of HIV testing for low-risk patients, but minimally increased the identification of HIV-positive patients due to lower acceptance rates among higher risk patients. It is possible that higher risk populations might demonstrate a more pronounced effect on HIV test acceptability with named reporting and mandatory partner notification. Even a delay in HIV testing is a critical clinical issue since shortened regimens of antiretroviral therapy have been shown to have decreased ability to prevent vertical transmission than the full original AIDS Clinical Trial Group 076 protocol. 8 This could mean that those infants most likely to need prenatal antiretroviral therapy may not receive it.
Further characterization of the women refusing perinatal testing or prenatal care and their reasons are critical. The close observation that characterizes prenatal care, along with its longitudinal nature, could provide a unique opportunity to further examine women who initially refuse HIV testing and then later accept HIV testing. This analysis may permit the generation of hypotheses for models of change and behavioral interventions to increase the acceptability of HIV testing in pregnancy. Additional studies addressing the impact of named reporting and mandatory partner notification in other pregnant populations, including those at highest risk, would be helpful prior to further implementation of named reporting and mandatory partner notification in other states. A strategy of prenatal exemption from named reporting and mandatory partner notification coupled with named reporting and mandatory parental notification of newborn data may be more constructive than the current approach.
